Using cure modelling for cost effectiveness in the NICE technology appraisal of Polatuzumab Vedotin in combination for untreated diffuse large B cell lymphoma: an external assessment group perspective
Using cure modelling for cost effectiveness in the NICE technology appraisal of Polatuzumab Vedotin in combination for untreated diffuse large B cell lymphoma: an external assessment group perspective
1177-1179
Cooper, Keith
ea064f58-d71d-404a-bcf3-49d243b8825b
Maund, Emma
c9733167-eafe-44e5-b418-5ace79161402
Takahashi, Marcia Tomie
fa084efd-dc46-4325-8fc9-d3f6d1f8b5d0
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
9 November 2024
Cooper, Keith
ea064f58-d71d-404a-bcf3-49d243b8825b
Maund, Emma
c9733167-eafe-44e5-b418-5ace79161402
Takahashi, Marcia Tomie
fa084efd-dc46-4325-8fc9-d3f6d1f8b5d0
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Cooper, Keith, Maund, Emma, Takahashi, Marcia Tomie and Shepherd, Jonathan
(2024)
Using cure modelling for cost effectiveness in the NICE technology appraisal of Polatuzumab Vedotin in combination for untreated diffuse large B cell lymphoma: an external assessment group perspective.
PharmacoEconomics, 42, .
(doi:10.1007/s40273-024-01421-8).
Text
Cooper et al. 2024 Pharmacoeconomics
- Accepted Manuscript
Restricted to Repository staff only until 9 November 2025.
Available under License Other.
Request a copy
More information
Accepted/In Press date: 21 July 2024
Published date: 9 November 2024
Identifiers
Local EPrints ID: 498065
URI: http://eprints.soton.ac.uk/id/eprint/498065
ISSN: 1170-7690
PURE UUID: 84b97949-4944-4a5b-a8e1-1385f0fe9adb
Catalogue record
Date deposited: 07 Feb 2025 17:31
Last modified: 08 Feb 2025 03:09
Export record
Altmetrics
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics